Answers are grounded in this paper and cite their sources.
RAS gene mutations play a major role in the development and progression of cancer. According to recent data, mutations in the RAS gene are responsible for nearly 30% of all cancer cases worldwide. Among these, KRAS mutations account for more than 85% of all RAS mutations and are particularly prevalent in aggressive malignancies, including colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC). In this manuscript, we provide a detailed discussion of the RAS signaling cascades and their regulatory mechanisms. The catalytic region of RAS proteins, which comprises the P-loop, Switch I and Switch II regions, and RAS-effector interaction surfaces, exhibits a high degree of structural conservation across the different RAS isoforms. Sotorasib was the first covalent KRAS inhibitor to receive regulatory approval and acts by irreversibly binding to the cysteine residue at position 12 (Cys12). In this manuscript, we discuss in detail targeted RAS inhibitors, including adagrasib (MRTX849), fulzerasib (IBI351), garsorasib (D-1553), glecirasib (JAB-21822), and divarasib (GDC-6036). Finally, we focus on recent advances in RAS inhibitor patents from 2019 to the present, with particular emphasis on thiazole, benzothiazole, quinazoline, and other emerging chemical scaffolds.
No takes yet. Share an insight, caveat, or question.
Chauhan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: